The multikinase BRAF inhibitor Sorafenib is currently the first-line treatment for radioiodine-refractory thyroid cancer; however, for Regorafenib, clinical data for differentiated thyroid cancer are still lacking; and for the selective BRAF inhibitors (Dabrafenib, Vemurafenib, Cobimetinib), insufficient evidence has been collected for FDA approval in PTC treatment. Here, BRAF is linked to thyroid cancer.